drugset / Trial / NCT02281136

Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick

NCT02281136

Phase 2 Completed 29 enrolled DUSA Pharmaceuticals, Inc.
NaSingle-groupOpen-label

Summary

The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.

Timeline

Start
2014-12
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent 20 % Topical

Indications